About 200 reports

The ranking system ranges from one (##) to five (##), with ## being the least favorable score and ## being the most favorable.

  • Cancer
  • Immunotherapy
  • Lymphoma
  • United States
  • Forecast

Radiation therapy being one of them.

  • Lymphoma
  • Forecast
  • Celgene Corporation
  • Seattle Genetics, Inc.
  • Takeda Pharmaceutical Company Limited

Biosimilars in Oncology Report Code: GDHCHT## Published: August 2018 Healthcare TABLE OF CONTENTS (##/ ##) ##.

  • Lymphoma
  • Biocon Limited
  • Mylan Inc.
  • Pfizer Inc.
  • Sandoz Inc.

Frontiers in Immunology; ##: ##.

  • Lymphoma
  • United States
  • Celgene Corporation
  • Gilead Sciences, Inc.
  • Novartis AG

FRAUNHOFER INSTITUTE FOR CELL THERAPY AND IMMUNOLOGY ##.

  • Lymphoma
  • Company
  • Market Size
  • Juno Therapeutics Inc.
  • Novartis AG

THERE IS A CLEAR FOCUS ON INVESTING IN IMMUNOLOGY DEVELOPMENT.

  • Lymphoma
  • AstraZeneca PLC
  • Novartis AG
  • Pfizer Inc.
  • Roche Group
  • GLOBAL MARKETS DIRECT REPORT COVERAGE

Its primary focus is on cancer, cardiovascular, immunology and virology (including hepatitis B, hepatitis C and HIV infection) therapeutic projects.

  • Lymphoma
  • Research And Development
  • United States
  • Product Initiative
  • Pfizer Inc.
  • Therapy Area Indication(s)

The prominent features of this report are - ##.

  • Lymphoma
  • Medical Biotechnology
  • Pharmaceutical
  • World
  • Product Initiative
  • GLOBAL MARKETS DIRECT REPORT COVERAGE

The company' s pipeline products comprise therapies such as SP-##-##, SP-##-##, SP-##-## and SP-##-##.

  • Cancer
  • Lymphoma
  • United States
  • World
  • Product Initiative
  • Clinical Trial profile. 307 Trial Title
  • Clinical Trial profile. 235 Trial Title

Hoffmann-La Roche Ltd ## ## ## ## ## ## ## ## Sanofi ## ## ## ## ## ## ## ## Johnson & Johnson ## ## ## ## ## ## ## ## Astellas Pharma Inc ## ## ## ## ## ## ## ## Takeda Pharmaceutical Co Ltd ## ## ## ## ## ## ## ## Incyte Corp ## ## ## ## ## ## ## ## Bellicum Pharmaceuticals Inc ## ##

  • Lymphoma
  • Monoclonal Antibody
  • Pharmaceutical
  • United States
  • World

[Accessed November ##, 2015].

  • Lymphoma
  • Japan
  • United States
  • World
  • Forecast
  • PIPELINE BY MEDIVIR AB, H1 2018
  • GLOBAL MARKETS DIRECT REPORT COVERAGE

It offers prescription products for treating cardiovascular, cancer, immunology, infectious, respiratory and women' s diseases, diabetes and vaccines.

  • Lymphoma
  • Oncology
  • United States
  • World
  • Acetylon Pharmaceuticals, Inc.
  • Global Markets Direct Report Coverage

From one-third to one-half of patients derived clinical benefit.

  • Lymphoma
  • Therapy
  • United States
  • Product Initiative
  • Amgen Inc.
  • PRODUCTS UNDER DEVELOPMENT BY COMPANIES, H1 2018 (CONTD..5), H1 2018
  • Tyrosine Protein Kinase SYK (Spleen Tyrosine Kinase or p72 Syk or SYK or EC 2.7.10.2) - Dormant Products

The company reported that it is preparing to conduct Phase II trials for Immunology indications.

  • Lymphoma
  • Pharmaceutical
  • Therapy
  • United States
  • Product Initiative
  • GLOBAL MARKETS DIRECT REPORT COVERAGE

Tissue inhibitor of metalloproteinase ## (TIMP-##) showed statistically significant reduction; mean change of TIMP-##, -##. ## IU, P=##. ##.

  • Hospital
  • Immunotherapy
  • Lymphoma
  • Therapy
  • TaiwanJ Pharmaceuticals Co., Ltd.
  • CLINICAL AND COMMERCIAL ATTRACTIVENESS

Current Topics in Microbiology and Immunology, ##, ##-## < DOI> ##. ##/ ##_2010_##< / DOI>.

  • Lymphoma
  • European Union
  • Japan
  • United States
  • Roche Group
  • RITUXAN / MABTHERA APPROVED INDICATIONS & PIPELINE - 1/3
  • ROCHE - 1/8

Mar- Roche Pipeline Presentation Jan ##, ket 2014 - Immunology sales of rituximab in 2013 were CHF ##, ## mln (+##% growth on CER basis) Product ROCHE - ##/ ## ID No.

  • Lymphoma
  • Biogen Idec Inc.
  • Boehringer Ingelheim GmbH
  • Celltrion, Inc.
  • Genentech, Inc.

THE COMPANY CURRENTLY HAS A WIDE RANGE OF TREATMENT OPTIONS AVAILABLE ACROSS VARIOUS THERAPEUTIC AREAS, INCLUDING ONCOLOGY, NEUROSCIENCE, OPHTHALMOLOGY, RESPIRATORY, AND IMMUNOLOGY AND DERMATOLOGY.

  • Lymphoma
  • North America
  • United States
  • Mirati Therapeutics, Inc.
  • Novartis AG
  • Introduction

This research has been reported in the Journal of Immunology.

  • Lymphoma
  • Pharmaceutical
  • United States
  • World
  • Product Initiative

The patients will be randomized ##:## to receive either resminostat or placebo.

  • Lymphoma
  • Targeted Therapy
  • United States
  • World
  • Product Initiative

THE FOCUSED THERAPEUTIC AREAS INCLUDE CARDIO METABOLIC, IMMUNOLOGY, INFECTIOUS DISEASES, ONCOLOGY AND RESPIRATORY DISEASES.

  • Lymphoma
  • North America
  • United States
  • Amgen Inc.
  • MedImmune, LLC
  • Global Markets Direct Report Coverage

From one-third to one-half of patients derived clinical benefit.

  • Lymphoma
  • Therapy
  • United States
  • Product Initiative
  • Amgen Inc.
  • GLOBAL MARKETS DIRECT REPORT COVERAGE

This research has been reported in the Journal of Immunology.

  • Lymphoma
  • United States
  • World
  • Product Initiative
  • Incyte Corporation

The results were published this week in the Cutting Edge section of the Journal of Immunology.

  • Autoimmune Disease
  • Lymphoma
  • Monoclonal Antibody
  • United States
  • Product Initiative
  • Clinical Trial profile. 97 Trial Title
  • Clinical Trial profile. 93 Trial Title

The prominent features of this report are - ##.

  • Autoimmune Disease
  • Lymphoma
  • Medical Biotechnology
  • World
  • Product Initiative
  • NANOSTRING ENTERS INTO CO-DEVELOPMENT AGREEMENT WITH CELGENE
  • Jan 08, 2018: Celgene Announces Preliminary 2017 Unaudited Results and 2018 Financial Guidance

The Company also announced the promotion of Scott Smith to President and COO, effective April ##, 2017, and the promotion of Terrie Curran to President, Global Inflammation & Immunology (I& I) Franchise, effective April ##, 2017.

  • Lymphoma
  • Pharmaceutical
  • Therapy
  • United States
  • Celgene Corporation

The company offers neurology and immunology; metabolic endocrinology, fertility and oncology products.

  • Biopharmaceutical
  • Lymphoma
  • Medical Biotechnology
  • United States
  • BioPharma company
  • PIPELINE BY SYNIMMUNE GMBH, H2 2018
  • GLOBAL MARKETS DIRECT REPORT COVERAGE

Immune Tolerance Network announced the AbATE study Phase II results in type ## diabetes were published in Science Immunology.

  • Immunotherapy
  • Lymphoma
  • World
  • Product Initiative
  • Amgen Inc.
  • Introduction

It has pipeline candidates in oncology, immunology, neuroscience, metabolism, infectious disease and ophthalmology.

  • Lymphoma
  • Therapy
  • United States
  • Product Initiative
  • Karyopharm Therapeutics Inc.
  • DORMANT PRODUCTS, H2 2018 (CONTD..1), H2 2018
  • PIPELINE BY HUTCHISON MEDIPHARMA LTD, H2 2018

The study lasted for ## year.

  • Lymphoma
  • Pharmaceutical
  • Therapy
  • United States
  • Product Initiative